title: Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.
abstract: The safety and efficiency of a novel method of rapid-infusion IV immunoglobulin (IVIg) were retrospectively reviewed in 50 patients with neuromuscular disorders. There were 89 adverse events after 341 rapid infusions (26%), 3.5% of which were considered to be major (requiring hospitalization) and 66% minor. All patients recovered without sequelae, and there were no deaths. Fourteen of 17 patients (82%) receiving maintenance therapy preferred rapid IVIg infusion because of its convenience. Rapid-infusion IVIg can be given safely and conveniently in many patients with neuromuscular disorders.
authors.affiliation: Division of Neurology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Grillo
authors.forename: K C
authors.initials: KC
authors.lastname: Gorson
authors.forename: A H
authors.initials: AH
authors.lastname: Ropper
authors.forename: J
authors.initials: J
authors.lastname: Lewis
authors.forename: R
authors.initials: R
authors.lastname: Weinstein
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009468:Neuromuscular Diseases / Q000628:therapy*; D010045:Outpatients; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous